Axcella Health Inc (NASDAQ:AXLA) Director David R. Epstein purchased 5,796 shares of Axcella Health stock in a transaction on Wednesday, July 10th. The stock was bought at an average cost of $8.24 per share, with a total value of $47,759.04. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Shares of NASDAQ:AXLA opened at $7.89 on Friday. Axcella Health Inc has a fifty-two week low of $7.70 and a fifty-two week high of $15.99. The business has a 50-day moving average of $11.44.

Axcella Health (NASDAQ:AXLA) last announced its quarterly earnings results on Thursday, June 20th. The company reported ($2.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($2.04). Sell-side analysts expect that Axcella Health Inc will post -3.05 EPS for the current fiscal year.

AXLA has been the subject of a number of analyst reports. JPMorgan Chase & Co. raised ROYAL MAIL PLC/ADR from an “underweight” rating to a “neutral” rating in a research report on Monday, June 3rd. Leerink Swann initiated coverage on Trevi Therapeutics in a research report on Monday, June 3rd. They issued an “outperform” rating for the company. Svb Leerink initiated coverage on Trevi Therapeutics in a research report on Monday, June 3rd. They issued an “outperform” rating and a $14.00 price target for the company. Finally, Goldman Sachs Group initiated coverage on Axcella Health in a research report on Sunday, June 2nd. They issued a “buy” rating and a $25.00 price target for the company.

Axcella Health Company Profile

There is no company description available for Axcella Health Inc

Featured Story: No Load Funds

Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.